MedTrace Logo

Dexamethasone for Symptom Burden in Advanced Cancer Patients

NCT00489307 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2025-11-12

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if dexamethasone can help to control symptoms such as fatigue, pain, nausea, weight loss, loss of appetite, sleep problems, and/or depression in patients with advanced cancer.

Conditions

Interventions

DRUG

Dexamethasone

4 mg PO (by mouth) twice daily x 14 days

DRUG

Placebo

Placebo PO twice daily x 14 days

Sponsors & Collaborators

  • American Cancer Society, Inc.

    collaborator OTHER

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Sriram Yennurajalingam, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-02
Primary Completion
2021-02-28
Completion
2028-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489307 on ClinicalTrials.gov